Olumiant 1mg 30ct 066 02
Olumiant Tablet, Film Coated
Product Images NDC 0002-4732
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Olumiant (NDC 0002-4732). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Eli Lilly And Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Olumiant 2mg 30ct 034 02
This is a prescription medication called Olumiant (baricitinib) in the form of 30 tablets. The recommended dosage is not given and further information can be obtained from the prescribing doctor. It is mandatory to dispense this medication with a medication guide. The NDC code for this medication is also provided.*
Olumiant 4mg 30ct 073 00
Structural Formula (Olumiant Uspi Chem V1)
Olumiant Uspi F1 V3
This text is providing information related to the recommended adjustments in intrinsic factor PK ratio and 90%CL for different demographics such as weight, age, and ethnicity. Additionally, it suggests adjustment recommendations for individuals with renal or hepatic impairment. The text also includes a table with ratios relative to a reference.*
Figure 2 (Olumiant Uspi F2 V1)
This appears to be a table showing recommendations for drug dosages and adjustments when coadministered with other drugs. The table includes PK ratios and 90% confidence limits for methotrexate, oral contraceptives containing ethinyl estradiol, and digoxin. However, the text is not particularly clear, so some details may be inaccurate.*
Olumiant Uspi F3 V3
This appears to be a table indicating the effects of various drugs and their potential interactions with each other. The table lists co-administered drugs, inhibitors, and inducers, and provides information on whether an adjustment in dosage is recommended or not. It also lists simulated versions of Ibuprofen and Diclofenac, Methotrexate, and Cyclosporine. The table shows the PK ratio and 90%Cl and a recommendation is provided for each drug-drug interaction.*
Olumiant Uspi F4 V2
The text shows a graph or chart comparing the percentage of responders to treatment with Olumiant, a 2 mg medication, versus a placebo. However, without more information or context, it is not possible to provide a specific description or interpretation of the data shown.*
Olumiant Uspi F5 V1
The text shows data from trial AA-1 and AA-2, with different doses of Olumiant compared to a placebo. The percentage of responders is shown for each treatment group. However, there is not enough information to determine what "responders" means, what condition was being treated, or what the purpose of the trials was.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
